Improvement in breast cancer survival has been observed in recent decades in the U.S., but it is unclear if similar survival gains are consistent across breast cancer subtypes, especially with regards to more advanced stages of the disease. Data were from 13 population-based cancer registries participating in the surveillance, epidemiology, and end results (SEER) program, consisting of women between 20 and 79 years of age diagnosed with invasive breast cancer between 1992 and 2008. 2-year (1992–2008) and 5-year (1992–2006) breast cancer cause-specific survival rates were calculated and stratified by estrogen receptor (ER)/progesterone receptor (PR) status, stage, and race. Annual percent changes in survival rates were assessed. From 1992 through 1998–1999, 5- and 2-year cause-specific survival rates significantly improved across ER+/PR+, ER−/PR−, and ER+/PR− subtypes, with an annual increase ranging from 0.5 to 1.0 % in the 5-year rates. From 1998–1999 to 2006, different patterns were observed by ER/PR subtypes with survival rates slightly improving for ER+/PR+, continuing to improve at a rate of 0.5 % per year for ER−/PR−, and dropping 0.3 % annually for ER+/PR−. No significant survival gains were experienced by patients with ER−/PR+ cancer during the study period. In terms of advanced diseases, greatest annual increases in survival rates were seen for patients with stage III–IV ER+/PR+ and ER−/PR− tumors but less progress was observed for advanced ER+/PR− breast cancers. Steady improvements in survival rates for breast cancer have been achieved over the past several decades. However, 5-year survival rates for stage IV disease remained dismally below 20 % for most ER/PR subtypes.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Howlader N, Noone AM, Krapcho M, et al (2013) SEER cancer statistics review, 1975–2010. http://seer.cancer.gov/csr/1975_2010/. Accessed 14 August 2014
Howlader N, Noone AM, Krapcho M, et al (2014) SEER cancer statistics review, 1975–2011. http://seer.cancer.gov/csr/1975_2010/. Accessed 14 August 2014
Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792
Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52
Holleczek B, Brenner H (2012) Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC Cancer 12:317
Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683–1690
Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6
Ademuyiwa FO, Groman A, Hong C-C et al (2013) Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Res Treat 138:241–248
Bartlett JMS, Brookes CL, Robson T et al (2011) Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29:1531–1538
Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065
Bleyer A, Welch HG (2012) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367:1998–2005
Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(Suppl 7):vii10–vii14
Smith RE, Good BC (2003) Chemoprevention of breast cancer and the trials of the national surgical adjuvant breast and bowel project and others. Endocr Relat Cancer 10:347–357
National cancer institute adjusted AJCC 6th ed. T, N, M, and stage—SEER documentation. http://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/. Accessed 23 Jun 2014
Statistical research and applications branch NCI jointpoint regression program, Version 4.0.1
Kim HJ, Fay MP, Feuer EJMD (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351
Bérubé S, Provencher L, Robert J et al (2007) Quantitative exploration of possible reasons for the recent improvement in breast cancer survival. Breast Cancer Res Treat 106:419–431
Dawood S, Broglio K, Gonzalez-Angulo AM et al (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26:4891–4898
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer recurrence and 15 year survival:an overview of the randomized trials. Lancet 365:1687–1717
Colozza M, de Azambuja E, Personeni N et al (2007) Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12:253–270
Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev 1:E1–E25
Mitri Z, Constantine T, O’Regan R (2012) The HER2 Receptor in Breast Cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502
Hammond MEH, Hayes DF, Wolff AC et al (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6:195–197
Cano G, Milanezi F, Leitão D et al (2003) Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol 29:207–211
Cheang MCU, Treaba DO, Speers CH et al (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637–5644
Welsh AW, Harigopal M, Wimberly H et al (2013) Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol 21:139–147
Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261
Yu K-D, Liu G-Y, Di G-H et al (2007) Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast 16:307–315
Carlson RW, Hudis CA, Pritchard KI (2006) Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Cancer Netw 4:971–979
Hunt BR, Whitman S, Hurlbert MS (2014) Increasing Black:white disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 38:118–123
Menashe I, Anderson WF, Jatoi I, Rosenberg PS (2009) Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101:993–1000
Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321
Gerend MA, Pai M (2008) Social determinants of Black–White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev 17:2913–2923
Silber JH, Rosenbaum PR, Clark AS et al (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389–397
Lepeak L, Tevaarwerk A, Jones N et al (2011) Persistence in breast cancer disparities between African Americans and whites in Wisconsin. WMJ 110:21–25
Jatoi I, Anderson WF, Rao SR, Devesa SS (2005) Breast cancer trends among black and white women in the United States. J Clin Oncol 23:7836–7841
DeLancey JOL, Thun MJ, Jemal A, Ward EM (2008) Recent trends in Black–White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev 17:2908–2912
Livaudais JC, Lacroix A, Chlebowski RT et al (2013) Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women’s health initiative. Cancer Epidemiol Biomarkers Prev 22:365–373
Fedewa SA, Ward EM, Stewart AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28:4135–4141
Sail K, Franzini L, Lairson D, Du X (2012) Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer. Ethn Health 17:309–323
Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839–846
Lehtimäki T, Lundin M, Linder N et al (2011) Long-term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res 13:R134
Population Characteristics—SEER registries. http://seer.cancer.gov/registries/characteristics.html. Accessed 31 Jan 2013
This work was supported in part by NCI (N01-PC95001). The dataset used for this analysis was obtained from the Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1992-2008), NCI, Department of Cancer Control and Population Sciences, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. The NCI and SEER program were not involved in the design and conduct of this study, in the analysis or interpretation of the data, or in the preparation and review of this article.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Chen, L., Linden, H.M., Anderson, B.O. et al. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat 147, 609–616 (2014). https://doi.org/10.1007/s10549-014-3112-6
- Breast cancer
- Estrogen receptor
- Progesterone receptor
- Time trend